11-valent recombinant human papillomavirus vaccine (China National Biotec Group)
11价重组人乳头瘤病毒疫苗（汉逊酵母，国药中生）
Report date: 2022/07/19 16:22:54
Base Information
Drug Name11-valent recombinant human papillomavirus vaccine (China National Biotec Group)
Drug Alias NameN/A
Classification
Mechanisms of Action
Targets
Therapy Area/Indications +[6]
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesChengdu Institute Of Biological Products Co LtdChina National Biotec Group Co LtdBeijing Institute Of Biological Products Co Ltd
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesNational Vaccine and Serum Institute, ChinaChengdu Institute Of Biological Products Co LtdBeijing Institute Of Biological Products Co Ltd +[4]
Inactive CompaniesN/A
Active Indications +[6]
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A